Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients
Open Access
- 4 November 2024
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 30 (13) , 1683-1688
Abstract
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs). Objectives: We investigated the longitudinal association between and predictive value of sNfL and sGFAP and the occurrence of WoS in MS patients treated with natalizumab. Methods: We performed longitudinal measurements of sNfL and sGFAP in NEXT-MS trial participants who completed a questionnaire about WoS. Results: A total of 364 participants were included. In total, 55.5% presented with WoS and 44.5% without WoS during natalizumab treatment. Longitudinal analyses showed no association between sNfL and sGFAP levels and WoS at any timepoint. Biomarker levels at baseline did not predict first-time WoS occurrence. Conclusion: Acute and chronic neuronal and axonal damage are most likely not the underlying cause of WoS.Keywords
Funding Information
- Stichting MS Research (18-1030)
- Hersenstichting
- Innovative Medicines Initiative (831434)
- Innovatiefonds Zorgverzekeraars
This publication has 9 references indexed in Scilit:
- Association of serum neurofilament light with microglial activation in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2023
- Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemicJournal of Neurology, 2022
- Blood GFAP as an emerging biomarker in brain and spinal cord disordersNature Reviews Neurology, 2022
- Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple SclerosisBiomolecules, 2022
- Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up studyJournal of the Neurological Sciences, 2020
- End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?Multiple Sclerosis and Related Disorders, 2020
- Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancyNeurology Neuroimmunology & Neuroinflammation, 2020
- The natalizumab wearing-off effectNeurology, 2019
- Neurofilaments as biomarkers in neurological disordersNature Reviews Neurology, 2018